PSI Developed A New Promising Radiopharmaceutical Successfully Tested A promising radiopharmaceutical against metastatic neuroendocrine tumours has been successfully tested for the first time in patients at the University Hospital Basel, Switzerland. The new radionuclide terbium-161 was developed at the Paul Scherrer Institute (PSI, ENS Corporate Member). This isotope has the property that when the radioisotope…
ENS HSC Position Paper “Nuclear Scientific Community for Global Sustainable Development” This interview has been published on NucNet – The Independent Nuclear News Agency, on 20th March 2024. NucNet is a Brussels-based independent news agency and information network for the global nuclear industry. It operates a 24/7 service reporting nuclear-related news about the operation and…
Urenco Signed An Important Nuclear Fuel Deal With Korea’s KHNP On Friday 22 March, Urenco (ENS Corporate Member) signed a new contract for the long-term supply of enrichment services with the operator of Korea’s nuclear power plants – Korea Hydro & Nuclear Power Company (KHNP) – helping to provide a secure, diverse and reliable supply…
Tractebel To Support PanTera’s Radioisotope Production Facility Tractebel (ENS Corporate Member), together with its partner MODULO architects, will support the design and construction of PanTera’s actinium-225 production facility in Belgium, enabling breakthrough cancer treatments. The PanTera facility will be built in Mol (Belgium) and is dedicated to the production of 225Ac via photonuclear activation on…